News Releases

Orchard Therapeutics, a global gene therapy leader, and Pharming Group, a global, commercial stage biopharmaceutical company, today announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic

Pharming announces the successful completion of patient enrolment in the  pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

Pharming Group announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021. Anurag and Robert will be the successors of Bruno Giannetti, who was Chief Operating Officer (2006 - 2019)

Pharming Group N.V. announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain.

Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Virtual Healthcare Conference 2021 at 14:30-14:55 CET/08:30-08:55 EDT on 4 June 2021.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.

Pharming Group N.V. supports the 10th annual “hae-day :-)”, the global awareness day for hereditary angioedema (HAE), a rare life-threatening condition.

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021.

Pharming Group N.V. announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial

Pharming Group N.V. announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S. Securities and Exchange Commission (SEC)